In vivo characterization of anti-atrial fibrillatory potential and pharmacological safety profile of INa,L plus IKr inhibitor ranolazine using the halothane-anesthetized dogs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Katzung BG (2018) Vasodilators & the treatment of angina pectoris. In: Katzung BG (ed) Basic and clinical pharmacology, 14th edn. McGraw-Hill Education, New York, pp 194–211
Geng M, Lin A, Nguyen TP (2020) Revisiting antiarrhythmic drug therapy for atrial fibrillation: reviewing lessons learned and redefining therapeutic paradigms. Front Pharmacol 11:581837
Harvey RD, Grant AO (2018) Agents used in cardiac arrhythmias. In: Katzung BG (ed) Basic and clinical pharmacology, 14th edn. McGraw-Hill Education, New York, pp 228–253
Lei M, Wu L, Terrar DA, Huang CL (2018) Modernized classification of cardiac antiarrhythmic drugs. Circulation 138:1879–1896
Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Corderio JM, Thomas G (2004) Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110:904–910
Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN (2006) Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17(Suppl 1):S169–S177
Sicouri S, Glass A, Belardinelli L, Antzelevitch C (2008) Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 5:1019–1026
Kumar K, Nearing BD, Carvas M, Nascimento BCG, Acar M, Belardinelli L, Verrier RL (2009) Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 20:796–802
Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CH, Molhoek P, Verheugt FWA, Gersh BJ, McCabe CH, Braunwald E (2007) Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116:1647–1652
Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V (2014) Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 16:973–979
Simopoulos V, Hevas A, Hatziefthimiou A, Dipla K, Skoularigis I, Tsilimingas N, Aidonidis I (2018) Amiodarone plus ranolazine for conversion of post-cardiac surgery atrial fibrillation: enhanced effectiveness in reduced versus preserved ejection fraction patients. Cardiovasc Drugs Ther 32:559–565
White CM, Nguyen E (2017) Novel use of ranolazine as an antiarrhythmic agent in atrial fibrillation. Ann Pharmacother 51:245–252
De Vecchis R, Ariano C, Giasi A, Cioppa C (2018) Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. Minerva Cardioangiol 66:349–359
Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, Zareba W, Rosero S, Kowey P, HARMONY Investigators (2015) The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circ Arrhythm Electrophysiol 8:1048–1056
Sugiyama A (2008) Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 154:1528–1537
Motokawa Y, Nakamura Y, Hagiwara-Nagasawa M, Goto A, Chiba K, Lubna NJ, Izumi-Nakaseko H, Ando K, Naito AT, Yamazaki H, Sugiyama A (2018) In vivo analysis of the anti-atrial fibrillatory, proarrhythmic and cardiodepressive profile of dronedarone as a guide for safety pharmacological evaluation of antiarrhythmic drugs. Cardiovasc Toxicol 18:242–251
Matsukura S, Nakamura Y, Cao X, Wada T, Izumi-Nakaseko H, Ando K, Naito AT, Sugiyama A (2017) Anti-atrial fibrillatory versus proarrhythmic potentials of amiodarone: a new protocol for safety evaluation in vivo. Cardiovasc Toxicol 17:157–162
Ishizaka T, Takahara A, Iwasaki H, Mitsumori Y, Kise H, Nakamura Y, Sugiyama A (2008) Comparison of electropharmacological effects of bepridil and sotalol in halothane-anesthetized dogs. Circ J 72:1003–1011
Johannesen L, Vicente J, Mason JW, Sanabria C, Waite-Labott K, Hong M, Guo P, Lin J, Sorensen JS, Galeotti L, Florian J, Ugander M, Stockbridge N, Strauss DG (2014) Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther 96:549–558
Hagiwara-Nagasawa M, Kambayashi R, Goto A, Nunoi Y, Izumi-Nakaseko M, Takei Y, Matsumoto A, Sugiyama A (2020) Cardiohemodynamic and arrhythmogenic effects of the anti-atrial fibrillatory compound vanoxerine in halothane-anesthetized dogs. Cardiovasc Toxicol 21:206–215
Sugiyama A, Hashimoto K (2002) Effects of a typical IKr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn J Pharmacol 88:414–421
Nagueh SF, Sun H, Kopelen HA, Middleton KJ, Khoury DS (2001) Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. J Am Coll Cardiol 37:278–285
Van de Water A, Verheyen J, Xhonneux R, Reneman RS (1989) An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 22:207–217
Ando K, Nakamura Y, Hagiwara-Nagasawa M, Harada H, Miyamoto H, Inamura N, Takagi K, Goto A, Chiba K, Lubna NJ, Izumi-Nakaseko H, Naito AT, Sugiyama A (2018) Comparison of electropharmacological effects between terfenadine and its active derivative fexofenadine using a cross-over study in halothane-anesthetized dogs to analyze variability of pharmacodynamic and pharmacokinetic profiles of terfenadine and torsadogenic risk of fexofenadine. J Toxicol Sci 43:183–192
Chiba K, Sugiyama A, Satoh Y, Shiina H, Hashimoto K (2000) Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol 169:8–16
Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Kugiyama K, Hashimoto K (2002) Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart assessed using the halothane-anesthetized in vivo canine model. Circ J 66:857–862
Virsolvy A, Farah C, Pertuit N, Kong L, Lacampagne A, Reboul C, Aimond F, Richard S (2015) Antagonism of Nav channels and α1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine. Sci Rep 5:17969